International Assets Investment Management LLC Purchases 5,705 Shares of Insulet Corporation $PODD

International Assets Investment Management LLC lifted its position in shares of Insulet Corporation (NASDAQ:PODD) by 7,815.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 5,778 shares of the medical instruments supplier’s stock after purchasing an additional 5,705 shares during the quarter. International Assets Investment Management LLC’s holdings in Insulet were worth $756,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allegiance Financial Group Advisory Services LLC acquired a new stake in Insulet in the 3rd quarter valued at $296,000. Claro Advisors Inc. acquired a new stake in shares of Insulet in the third quarter valued at about $268,000. Capstone Wealth Management LLC acquired a new stake in shares of Insulet in the third quarter valued at about $240,000. Inscription Capital LLC acquired a new position in Insulet during the 3rd quarter worth approximately $290,000. Finally, Chicago Partners Investment Group LLC boosted its holdings in Insulet by 48.8% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 13,883 shares of the medical instruments supplier’s stock worth $2,069,000 after acquiring an additional 4,553 shares during the period.

Analysts Set New Price Targets

PODD has been the topic of a number of analyst reports. Robert W. Baird set a $175.00 price objective on shares of Insulet in a research note on Thursday, August 6th. Royal Bank Of Canada raised their target price on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Sanford C. Bernstein lifted their price target on shares of Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Canaccord Genuity Group reduced their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $185.67.

Insulet Stock Performance

PODD stock opened at $148.06 on Wednesday. The stock’s 50 day simple moving average is $142.05 and its 200 day simple moving average is $175.32. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The firm has a market cap of $10.27 billion, a P/E ratio of 24.11, a P/E/G ratio of 1.14 and a beta of 1.06. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same quarter in the previous year, the firm earned $1.24 earnings per share. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, equities research analysts predict that Insulet Corporation will post 6.75 EPS for the current year.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Truist raised its price target to $160 from $153 while maintaining a “hold” rating, implying potential upside from the cited share price. Truist price target
• Positive Sentiment: A separate report said Insulet’s growth characteristics could help it outperform the market, though it did not provide specific new financial guidance. Zacks growth-stock analysis
• Neutral Sentiment: Insulet launched a World Diabetes Day campaign encouraging people with diabetes to prioritize well-being. The initiative may support awareness but does not indicate a direct near-term financial impact. World Diabetes Day campaign
• Neutral Sentiment: A short-interest update reported zero shares sold short and a 0.0-day days-to-cover ratio, despite describing short interest as having increased. The figures therefore do not point to meaningful short-squeeze activity.

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.